Navigation Links
New inhibitor has potential as cancer drug
Date:10/22/2007

Laboratory experiments have previously shown that cancer cells overproduce an enzyme, heparanase, which splits the bodys own polysaccharide heparan sulfate into shorter fragments. The amount of enzyme is related to the degree of malignancy. Today a study is being published in the journal Nature Chemical Biology in which Uppsala University researchers show, on the basis of animal models, that an inhibitor for heparanase would be extremely interesting as a drug candidate.

Heparan sulfate is a polysaccharide, that is, a chain of linked sugar units, with sulfate groups in different positions. These chains are found on the surface of practically every cell in the body. The sulfate groups enable binding to a number of proteins, such as inflammation proteins and growth factors. Heparan sulfate can thereby regulate different processes in the body, during embryonic development, for example, but also in various conditions of sickness. The capacity for protein-binding generally increases the more sulfate groups there are on the polysaccharide.

The enzyme heparanase splits heparan sulfate at certain points and converts the long chains into shorter fragments. Research at other laboratories has shown that cancer cells in many cases overproduce heparanase and that the amount of heparanase correlates with the degree of malignancy of the cancer cells and their capacity to metasthesize. The connection is believed to have multiple explanations. Heparanase helps cancer cells make their way through tissue barriers, but it also stimulates the heightened generation of blood vessels that is necessary for tumor growth. The fragments function as carriers of growth factors that can promote tumor growth in many ways.

In the current project the scientists introduced the gene for human heparanase into a mouse, so that the enzyme would be overproduced in several organs. Besides the expected splitting of heparan sulfate, they found that the metabolism of the polysaccharide was stimulated, but that the number of sulfate groups increased at the same time. The high-sulfated fragments released by the enzyme evince dramatically increased binding to certain growth factors of potential importance to tumor growth. When they examined heparan sulfate from authentic cancer cells instead, or from cancer tissue that had overproduced heparanase, it was found that here too there was an increase in the number of sulfate groups compared with heparan sulfate from corresponding normal cells/tissues. The findings indicate that producing an inhibitor for heparanase is an urgent step in discovering new drugs for cancer.


'/>"/>

Contact: Jin-ping Li
Jin-ping.Li@imbim.uu.se
46-018-471-4241
Uppsala University
Source:Eurekalert

Related biology news :

1. HIV Patients May Be at Risk of Heart Problems When Taking Protease Inhibitor Drugs
2. Breast Cancer May Be Uniquely Sensitive To Inhibitors Of PI3K Pathway
3. Anthrax inhibitors identified by Burnham team
4. Protease inhibitors reach beyond HIV
5. UNC scientists discover new role for protein as fundamental inhibitor of cell movement
6. Small molecule inhibitor of cholera discovered
7. Enzyme inhibitors block replication of SARS virus
8. Scientists design potent anthrax toxin inhibitor
9. Sweet water taste paradoxically predicts sweet taste inhibitors
10. Anthrax inhibitor counteracts toxin, may lead to new therapeutics
11. COX-2 inhibitors significantly reduce risk of cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... 2016  higi SH llc (higi) announced today ... national brands, industry thought-leaders and celebrity influencers looking ... for taking steps to live healthier, more active ... higi has built the largest self-screening health station ... people who have conducted over 185 million biometric ...
(Date:11/28/2016)... 2016 "The biometric system ... The biometric system market is in the growth ... near future. The biometric system market is expected to ... a CAGR of 16.79% between 2016 and 2022. Government ... technology in smartphones, rising use of biometric technology in ...
(Date:11/21/2016)... Nov. 21, 2016   Neurotechnology , a ... technologies, today announced that the MegaMatcher On Card ... submitted for the NIST Minutiae Interoperability Exchange ... the mandatory steps of the evaluation protocol. ... continuing test of fingerprint templates used to establish ...
Breaking Biology News(10 mins):
(Date:12/2/2016)... 2, 2016 Research and Markets has ... Applications, Markets and Companies" to their offering. ... , , ... pharmaceutical and biotechnology industries is anticipated. Nanotechnology will be applied ... optimal delivery to diagnostic applications in clinical trials. Many of ...
(Date:12/2/2016)... York, NY (PRWEB) , ... December 01, 2016 , ... ... event is expanding to three days and will take place on February 1-3, 2017 ... (GSK) and Dr James Gulley (NCI), the program provides a unique 360-degree approach, which ...
(Date:12/2/2016)... NEW YORK , Dec. 1, 2016   ... liquid photopurification, announced today that the Company has concluded ... has the right for a 90-day period to acquire ... invoice value of approximately USD 3.7 million.  ... an agreement with Tamarack under which Tamarack will seek ...
(Date:11/30/2016)... York , November 30, 2016 ... as a few players hold a dominant share in ... Charles River Laboratories International, Inc., and Merck KGaA, held ... in 2015. Transparency Market Research observes that these companies ... focused on development products that are do not require ...
Breaking Biology Technology: